Citigroup Upgrades CRISPR Therapeutics to Buy, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has upgraded CRISPR Therapeutics (NASDAQ:CRSP) from Neutral to Buy, while maintaining a $70 price target.
August 18, 2023 | 3:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CRISPR Therapeutics has been upgraded from Neutral to Buy by Citigroup, with a maintained price target of $70.
The upgrade from Neutral to Buy by Citigroup indicates a positive outlook for CRISPR Therapeutics. This could potentially lead to an increase in the stock's price in the short term, especially if other investors follow Citigroup's recommendation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100